许岚，女，现就职于上海交通大学医学院公共卫生学院流行病与生物统计学系。2020年9月毕业于比利时根特大学医学与健康学院，获流行病与生物统计学博士学位，留学期间获得国家留学基金委颁发的2018年度国家优秀自费留学生奖学金。博士期间的主要研究方向是与人乳头瘤病毒（HPV）相关的癌症和癌前病变的一级和二级预防，博士期间共发表SCI论文20余篇，国际会议论文9篇，其中第一作者SCI论文8篇。尤其擅长使用循证医学的分析方法解决临床问题。
主要研究方向:
1. 宫颈癌和其他与HPV相关癌症及癌前病变的预防控制的研究、技术转化和人群推广
2. 心血管疾病流行病学
主要研究成果：
1. Xu L, Ostrebenk A, Poljak M, Arbyn M. Evaluation and optimization of the clinical accuracy of Hybribio’s 14 High-risk HPV with 16/18 Genotyping assay within the VALGENT-3 framework. Journal of Clinical Microbiology 2020; 58.
2. Xu L, Selk A, Garland SM, Bogliatto F, Kyrgiou M, Weyers S, Arbyn M. Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors. Expert Review of Vaccines 2019;18(11):1157-1166.
3. Xu L, Benoy I, Cuschieri K, Poljak M, Bonde J and Arbyn M. Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies. Expert Review of Molecular Diagnostics 2019; 19(6): 543-51.
4. Benoy I*, Xu L*, Vanden Broeck D, Poljak M, Oštrbenk Valenčak A, Arbyn M, Bogers J. Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay 2019. J Clin Virol 120:57–62.
*Joint first authors
5. Xu L, Padalko E, Ostrebenk A, Poljak M, Arbyn M. Clinical evaluation of INNO-LiPA HPV Genotyping EXTRA II assay using the VALGENT framework. International Journal of Molecular Sciences 2018;19(9).pii:E2704.
6. Arbyn M*, Xu L*, Simons C, Martin-Hirsch PPL. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews 2018, Issue 5. Art. No.: CD009069.
*Joint first authors
7. Xu L, Ostrebenk A, Poljak M, Arbyn M. Assessment of the Roche Linear Array HPV Genotyping test within the VALGENT framework. Journal of Clinal Virology 2018; 98:37-42.
8. Xu L, Verdoodt F, Wentzensen N, Bergeron C, Arbyn M. Triage of ASC-H: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer. Cancer Cytopathology 2016;124: 261-72.
9. Arbyn M, Xu L, Verdoodt F, et al. Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis. Ann Intern Med 2017;166: 118-27.
